Iatrogenic Creutzfeldt-Jakob disease in Australia: Time to amend infection control measures for pituitary hormone recipients?

Medical Journal of Australia

Volumn 193, Issue 6, 2010, Pages 366-369

  Boyd, Alison ^a   Klug, Genevieve M J A ^a   Schonberger, Lawrence B ^b   McGlade, Amelia ^a   Brandel, Jean Philippe ^c   Masters, Colin L ^a   Collins, Steven J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c Hospitalier Pití Salpêtrìre   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GONADOTROPIN; HUMAN GROWTH HORMONE; TISSUE EXTRACT;

AUSTRALIA; DISEASE ASSOCIATION; DISEASE COURSE; IATROGENIC CREUTZFELDT JAKOB DISEASE; INFECTION CONTROL; INFERTILITY; MORTALITY; OUTCOME ASSESSMENT; REVIEW; RISK FACTOR; SHORT STATURE; ADENOHYPOPHYSIS; CHEMISTRY; CREUTZFELDT-JAKOB SYNDROME; HUMAN; IATROGENIC DISEASE; RISK ASSESSMENT; TRANSMISSION;

AUSTRALIA; CREUTZFELDT-JAKOB SYNDROME; HUMAN GROWTH HORMONE; HUMANS; IATROGENIC DISEASE; INFECTION CONTROL; PITUITARY GLAND, ANTERIOR; RISK ASSESSMENT; TISSUE EXTRACTS;

EID: 77957658747     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03951.x     Document Type: Review

References (26)

1. Allars M. Report of the inquiry into the use of pituitary derived hormones in Australia and Creutzfeldt-Jakob disease. Canberra: AGPS, 1994.
2. Koch TK, Berg BO, De Armond SJ, Gravina RF. Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism. Possible relation to the administration of cadaveric human growth hormone. N Engl J Med 1985; 313: 731-733.
3. World Health Organization. WHO manual for surveillance of human transmissible spongiform encephalopathies including variant Creutzfeldt-Jakob disease. Geneva: WHO, 2003. http://whqlibdoc.who.int/publications/2003/ 9241545887.pdf (accessed Jul 2010).
4. Australian Government Department of Health and Ageing. The use of human pituitary hormones in Australia and Creutzfeldt-Jakob disease (CJD). Key facts and figures. Canberra: DoHA, 1999.
5. The New Zealand Creutzfeldt-Jakob Disease Registry (Pollock M). Creutzfeldt-Jakob disease surveillance in New Zealand. Eighth annual report, January 2004 - December 2004. The NZ CJD Registry, 2005. (Available from the NZ CJD Registry.)
6. The National CJD Surveillance Unit. Creutzfeldt-Jakob disease surveillance in the UK. Seventeenth annual report, 2008. Edinburgh: The National CJD Surveillance Unit, 2009.
7. The New Zealand Creutzfeldt-Jakob Disease Registry (Pollock M). Creutzfeldt-Jakob disease surveillance in New Zealand. Seventh annual report, January 2003 - December 2003. The NZ CJD Registry, 2004. (Available from the NZ CJD Registry.)
8. Swerdlow AJ, Higgins CD, Adlard P, et al. Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone. Neurology 2003; 61: 783-791. (Pubitemid 37174473)
9. Klug GM, Boyd A, McGlade A, et al. Surveillance of Creutzfeldt-Jakob disease in Australia: 2010. Commun Dis Intell 2010; 34: 96-101.
10. Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 2006; 129 (Pt 9): 2278-2287.
11. Tschampa H, Zerr I, Urbach H. Radiological assessment of Creutzfeldt-Jakob disease. Eur Radiol 2007; 17: 1200-1211.
12. Croes E, Roks G, Jansen GH, et al. Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone. J Neurol Neurosurg Psychiatry 2002; 72: 792-793. (Pubitemid 34557026)
13. Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000; 55: 1075-1081.
14. National Institutes of Health. National Endocrine and Metabolic Diseases Information Service. National Hormone and Pituitary Program: information for people treated with pituitary human growth hormone (summary). http://www.endocrine.niddk.nih.gov/pubs/creutz/update.htm (accessed Jul 2010).
15. Huillard d'Aignaux J, Costagliola D, Maccario J, et al. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. Neurology 1999; 53: 1197-1201.
16. Brown P, Gibbs CJ Jr, Amyx HL, et al. Chemical disinfection of Creutzfeldt-Jakob disease virus. N Engl J Med 1982; 306: 1279-1282. (Pubitemid 12100211)
17. Taylor DM. Inactivation of transmissible degenerative encephalopathy agents: a review. Vet J 2000; 159: 10-17.
18. Taylor DM, Dickinson AG, Fraser H, et al. Preparation of growth-hormone free from contamination with unconventional slow viruses. Lancet 1985; 2: 260-262. (Pubitemid 15047554)
19. Taylor DM. Membrane filtration and the Creutzfeldt-Jakob agent. Lancet 1985; 2: 1430-1431.
20. Pocchiari M, Peano S, Conz A, et al. Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination. Horm Res 1991; 35: 161-166.
21. Fradkin JE, Schonberger L, Mills JL, et al. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. JAMA 1991; 265: 880-884.
22. Brandel J-P, Preece M, Brown P, et al. Distribution of codon 129 in human growth hormone-treated CJD patients in France and the UK. Lancet 2003; 362: 128-130. (Pubitemid 36831026)
23. Cooke J. Cannibals, cows and the CJD catastrophe. Sydney: Random House, 1998: 224.
24. Australian Government Department of Health and Ageing. Infection control guidelines for the prevention of transmission of infectious diseases in the health care setting 2007. http://www.health.gov.au/internet/main/publishing.nsf/ Content/icg-guidelines-index.htm (accessed Jul 2010).
25. Alpers MP. Review. The epidemiology of kuru: monitoring the epidemic from its peak to its end. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3707-3713.
26. Health Protection Agency, Health Protection Scotland. Patients at increased risk of Creutzfeldt-Jakob disease. Actions for healthcare staff. 2009. http://www.hpa.org.uk/web/HPAwebFile/HPAweb-C/1234602045948 (accessed Jul 2010).